Myeloid-Derived Suppressor Cells: A Multifaceted Accomplice in Tumor Progression

被引:16
|
作者
Cheng, Jia-Nan [1 ,2 ]
Yuan, Yi-Xiao [1 ,2 ,3 ]
Zhu, Bo [1 ,2 ]
Jia, Qingzhu [1 ,2 ]
机构
[1] Third Mil Med Univ, Xinqiao Hosp, Dept Oncol, Chongqing, Peoples R China
[2] Chongqing Key Lab Immunotherapy, Chongqing, Peoples R China
[3] Kunming Med Univ, Dept Thorac Surg, Affiliated Hosp 3, Kunming, Yunnan, Peoples R China
关键词
MDSC; Treg; EMT; angiogenesis; immunotherapy; NITRIC-OXIDE SYNTHASE; TRANS-RETINOIC ACID; REGULATORY T-CELLS; ANTI-VEGF THERAPY; TGF-BETA; IMMUNE-RESPONSE; IMMUNOSUPPRESSIVE ACTIVITY; PERIPHERAL-BLOOD; DENDRITIC CELLS; POOR-PROGNOSIS;
D O I
10.3389/fcell.2021.740827
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Myeloid-derived suppressor cell (MDSC) is a heterogeneous population of immature myeloid cells, has a pivotal role in negatively regulating immune response, promoting tumor progression, creating pre-metastases niche, and weakening immunotherapy efficacy. The underlying mechanisms are complex and diverse, including immunosuppressive functions (such as inhibition of cytotoxic T cells and recruitment of regulatory T cells) and non-immunological functions (mediating stemness and promoting angiogenesis). Moreover, MDSC may predict therapeutic response as a poor prognosis biomarker among multiple tumors. Accumulating evidence indicates targeting MDSC can reverse immunosuppressive tumor microenvironment, and improve therapeutic response either single or combination with immunotherapy. This review summarizes the phenotype and definite mechanisms of MDSCs in tumor progression, and provide new insights of targeting strategies regarding to their clinical applications.
引用
收藏
页数:13
相关论文
共 50 条
  • [41] History of myeloid-derived suppressor cells
    Talmadge, James E.
    Gabrilovich, Dmitry I.
    [J]. NATURE REVIEWS CANCER, 2013, 13 (10) : 739 - U79
  • [42] Myeloid-derived suppressor cells in transplantation
    Dilek, Nahzli
    van Rompaey, Nicolas
    Le Moine, Alain
    Vanhove, Bernard
    [J]. CURRENT OPINION IN ORGAN TRANSPLANTATION, 2010, 15 (06) : 765 - 768
  • [43] Myeloid-derived suppressor cells in gliomas
    Gieryng, Anna
    Kaminska, Bozena
    [J]. WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, 2016, 20 (05): : 345 - 351
  • [44] Myeloid-derived suppressor cells in glioma
    Mirghorbani, Masoud
    Van Gool, Stefaan
    Rezaei, Nima
    [J]. EXPERT REVIEW OF NEUROTHERAPEUTICS, 2013, 13 (12) : 1395 - 1406
  • [45] On the origin of myeloid-derived suppressor cells
    Millrud, Camilla Rydberg
    Bergenfelz, Caroline
    Leandersson, Karin
    [J]. ONCOTARGET, 2017, 8 (02) : 3649 - 3665
  • [46] EBV and myeloid-derived suppressor cells
    Sinha, Debottam
    Khanna, Rajiv
    [J]. BLOOD, 2021, 137 (02) : 148 - 150
  • [47] Myeloid-Derived Suppressor Cells and Radiotherapy
    Jimenez-Cortegana, Carlos
    Galassi, Claudia
    Klapp, Vanessa
    Gabrilovich, Dmitry, I
    Galluzzi, Lorenzo
    [J]. CANCER IMMUNOLOGY RESEARCH, 2022, 10 (05) : 545 - 557
  • [48] Myeloid-derived suppressor cells in cancer
    Bronte, Vincenzo
    [J]. JOURNAL OF IMMUNOTHERAPY, 2007, 30 (08) : 878 - 878
  • [49] History of myeloid-derived suppressor cells
    James E. Talmadge
    Dmitry I. Gabrilovich
    [J]. Nature Reviews Cancer, 2013, 13 : 739 - 752
  • [50] Myeloid-Derived Suppressor Cells in Sepsis
    Lai, Dengming
    Qin, Chaojin
    Shu, Qiang
    [J]. BIOMED RESEARCH INTERNATIONAL, 2014, 2014